C. Light Technologies Announces Activities and New Partnerships at ARVO

At this year’s Association for Research in Vision and Ophthalmology (ARVO), C. Light Technologies will meet with colleagues at booth #2424 to share engineering and software development updates from their new pipeline instrument, the Retitrack.  

"We will be looking to interact with scientific and business leaders within the pharmaceutical and CRO spaces to collaborate on exploratory endpoint trials in the neurodegenerative field," said Christy K. Sheehy, PhD, founder of C. Light Technologies.

The Retitrack is intended for recording, viewing, measuring, and analyzing temporal characteristics of fixation and saccadic responses. It is desinged to provide users with a summary report objectively quantifying both fixation (drift and microsaccade characteristics) as well as saccades.

In a recent move, C. Light Technologies and ophthalmic research organization Ora have announced a collaborative working relationship.

“We’re excited to expand our fixation and saccade metrics as potential exploratory endpoints into new ophthalmic drug trials. We look forward to pairing our high tracking sensitivity - an invaluable functional output - with Ora’s 40+ years of drug development knowhow," Dr. Sheehy said.

Dr. Mark Abelson, founder of Ora stated, "We are pleased to be working with C. Light and are excited about their technology. We look forward to the validation and incorporation of their device into our clinical trial designs in the largest untreated area of ophthalmology—early AMD”.

In addition to showcasing the Retitrack at the booth, C. Light has two poster presentations at the ARVO conference – one in person on May 4 showcasing the Retitrack design and outputs, entitled “A Novel Tracking Scanning Lase Ophthalmoscope (TSLO) System for Fixation and Saccade Quantification,” presented by Mark Mackanos, PhD; with the other poster detailing their recent advances utilizing machine learning and AI to track eye motion. The latter will be presented at the virtual ARVO conference by Joe Xing, PhD and is entitled “Retinal Task Detection and Image Perception using end-to-end Deep Neural Network (DNN) Based Algorithms.”

“Pre-commercialization efforts have been ramping up immensely, with FDA submission slated for next month.  Additionally, our team has solidified 20 letters of intent to purchase and collaborate from top tier institutions in both the ophthalmology and neuro spaces," said Dr. Sheehy.  Funding for C. Light has been secured through grant mechanisms provided by the NIH and Alzheimer’s Drug Discovery Foundation (ADDF), as well as through venture capital.